RELYVRIO
Total Payments
$5.1M
Transactions
3,151
Doctors
1,084
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.8M | 789 | 258 |
| 2023 | $3.3M | 2,362 | 966 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.4M | 630 | 87.2% |
| Honoraria | $321,831 | 205 | 6.3% |
| Consulting Fee | $104,382 | 18 | 2.1% |
| Space rental or facility fees (teaching hospital only) | $82,900 | 14 | 1.6% |
| Food and Beverage | $75,643 | 2,109 | 1.5% |
| Travel and Lodging | $43,043 | 130 | 0.8% |
| Grant | $22,500 | 2 | 0.4% |
| Education | $1,280 | 43 | 0.0% |
Payments by Type
Research
$4.4M
630 transactions
General
$651,580
2,521 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A35-009 | Amylyx Pharmaceuticals, Inc. | $1.4M | 0 |
| Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment (Phoenix) | Amylyx Pharmaceuticals, Inc. | $1.0M | 0 |
| A Phase II Study of Safety and Efficacy of AMX0035 in Adult Patients With Wolfram Syndrome | Amylyx Pharmaceuticals, Inc. | $911,085 | 0 |
| An Intermediate Size Expanded Access Protocol of AMX0035 for ALS | Amylyx Pharmaceuticals, Inc. | $638,012 | 0 |
| Single cohort Real World Experience with Relyvrio for ALS: A Retrospective Chart Review | Amylyx Pharmaceuticals, Inc. | $221,000 | 0 |
| A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS) | Amylyx Pharmaceuticals, Inc. | $158,600 | 0 |
| A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AMX0035 VERSUS PLACEBO FOR 48-WEEK TREATMENT OF ADULT PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) | Amylyx Pharmaceuticals, Inc. | $120,923 | 0 |
| A Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS | Amylyx Pharmaceuticals, Inc. | $14,144 | 0 |
| Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment (Phoenix) | Amylyx Pharmaceuticals, Inc. | $7,451 | 0 |
| A35-004 | Amylyx Pharmaceuticals, Inc. | $6,001 | 0 |
Top Doctors Receiving Payments for RELYVRIO
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Mercedes Foster | — | North Las Vegas, NV | $4.6M | 652 |
| , MD, PHD | Neuromuscular Medicine | Charlestown, MA | $73,636 | 9 |
| , M.D | Neurology | Lincoln, NE | $58,975 | 86 |
| , MD | Clinical Neurophysiology | Fresno, CA | $36,081 | 31 |
| , NP | Gerontology | Portland, OR | $26,062 | 50 |
| , M.D. PH.D | Neurology | Durham, NC | $21,780 | 19 |
| , M.D | Neurology | Columbus, OH | $19,799 | 38 |
| , M.D | Neurology | Los Angeles, CA | $16,445 | 20 |
| , MD | Neurology | Seattle, WA | $15,542 | 19 |
| , CRNP | Family | Baltimore, MD | $15,320 | 29 |
| , DNP,FNP-C | Nurse Practitioner | Fort Lauderdale, FL | $13,694 | 13 |
| , FNP-C | Family | Phoenix, AZ | $11,883 | 24 |
| , MD | Neurology | Philadelphia, PA | $11,419 | 6 |
| Jerrica Farias | Nurse Practitioner | Tampa, FL | $11,337 | 4 |
| , M.D | Neurology | Dallas, TX | $10,337 | 45 |
| , M.D | Neurology | Phoenix, AZ | $9,043 | 6 |
| , M.D., FRCP | Neurology | Burlington, VT | $8,153 | 13 |
| , MD | Clinical Neurophysiology | Hershey, PA | $8,099 | 9 |
| , M.D | Neurology | Hershey, PA | $5,604 | 12 |
| , M.D | Gastroenterology | Boston, MA | $5,250 | 1 |
| , M.D | Neurology | New York, NY | $4,968 | 5 |
| , M.D., M.P.H | Neurology | Boston, MA | $4,725 | 1 |
| , MD, PHD | Neuromuscular Medicine | Chicago, IL | $4,379 | 6 |
| , RPA-C | Surgical | Amherst, NY | $4,319 | 19 |
| , MD | Neurology | Fort Lauderdale, FL | $4,199 | 4 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $5.1M
- Total Doctors 1,084
- Transactions 3,151
About RELYVRIO
RELYVRIO is a drug associated with $5.1M in payments to 1,084 healthcare providers, recorded across 3,151 transactions in the CMS Open Payments database. The primary manufacturer is Amylyx Pharmaceuticals, Inc..
Payment data is available from 2023 to 2024. In 2024, $1.8M was paid across 789 transactions to 258 doctors.
The most common payment nature for RELYVRIO is "Unspecified" ($4.4M, 87.2% of total).
RELYVRIO is associated with 10 research studies, including "A35-009" ($1.4M).